Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

1:29FILE-ThiscombooffileimagesshowsFacebookCEOMarkZuckerberg,left,andTeslaandSpaceXCEOElonMusk.ElonM Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem




hotspot

author：hotspot    Page View：93546
An army of wooden figures under blue and pink lighting — biotech coverage from STAT
Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

advertisement

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： In medicine, common shorthands can shortchange care
Next article： Continuity nursing helped my family in our darkest PICU moments